Brian Park, PharmD

Drug Information Specialist https://www.pulmonologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Lung Infection

FDA Fast Tracks Brilacidin for COVID-19 Treatment

Brian Park, PharmD

January 19, 2021

The Food and Drug Administration has granted Fast Track designation to brilacidin for the treatment of COVID-19.

Pneumonia

Priority Review Granted to Novel Pneumococcal Conjugate Vaccine V114

Brian Park, PharmD

January 15, 2021

The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.

Lung Infection

FDA: SARS-CoV-2 Mutations May Impact Molecular Tests

Brian Park, PharmD

January 13, 2021

The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.

Lung Cancer

Tiragolumab Gets Breakthrough Therapy Status for PD-L1-High NSCLC

Brian Park, PharmD

January 12, 2021

Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.

Lung Infection

False Results Possible With Curative SARS-Cov-2 Test, Says FDA

Brian Park, PharmD

January 8, 2021

The test should be utilized in accordance with its Emergency Use Authorization and as described in the authorized labeling to reduce the risk of false negative results.

Lung Cancer

Nivolumab No Longer FDA-Approved for Small Cell Lung Cancer

Brian Park, PharmD

January 8, 2021

In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.

Lung Cancer

Lorlatinib Under Review for Previously Untreated ALK-Positive NSCLC

Brian Park, PharmD

January 7, 2021

The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.

Lung Infection

Phase 3 Trial of Novavax’s COVID-19 Vaccine Begins

Brian Park, PharmD

January 4, 2021

The vaccine candidate contains the Company’s saponin-based Matrix-M™ adjuvant technology to enhance and prolong immune responses.

Obstructive Lung Disease

FDA Expands Use of Multiple Cystic Fibrosis Medications

Brian Park, PharmD

December 29, 2020

The full list of CFTR gene mutations for Trikafta, Symdeko and Kalydeco can be found in the updated prescribing information for each respective product.